alpelisib
MSK to Launch Trial of T-Cell Receptor Therapy Targeting Common Neoantigen With Pharma Partner
Premium
The therapy, which could potentially have tissue-agnostic use, is designed to target a public neoantigen from a mutation in the oncogenic driver gene PIK3CA.
NICE Recommends Against Piqray Combo for PIK3CA-Mutated Metastatic Breast Cancer
The committee said it saw no direct evidence in favor of Piqray-fulvestrant when comparing it against standard treatments and found the cost-effectiveness estimates too high.
Kura Oncology Begins Trial of Tipifarnib, Novartis' Piqray in Head and Neck Cancer
The Phase I/II trial will enroll patients with recurrent or metastatic HRAS- or PIK3CA-dependent head and neck cancer.
Breast Cancer Study Shows Number of Mutated PIK3CA Alleles Affects Tumor Aggressiveness
Studies in breast tumors revealed a "biphasic"Â relationship between mutant PIK3CA allele dosage and stem cell-like features as well as aggressiveness.
Novartis, Kura Oncology Partner on Phase I/II Head and Neck Cancer Study of Piqray, Tipifarnib
Researchers will evaluate the combination of the two companies' drugs in head and neck cancer patients with HRAS or PIK3CA tumor markers.